{"prompt": "['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', '2.', 'INTRODUCTION', '2.1.', 'Study Rationale', 'Chronic obstructive pulmonary disease (COPD) is associated with poor health-related', 'quality of life (HRQoL). Pharmacologic therapy is used to improve lung function, reduce', 'symptoms, frequency and severity of exacerbations, and improve patients HRQoL', '[GOLD, 2015]. Umeclidinium/Vilanterol (UMEC/VI 62.5/25 mcg) is indicated for the', 'maintenance treatment of COPD that contain long-acting muscarinic antagonist (LAMA)', 'and long-acting beta2-agonist (LABA) bronchodilators. Umeclidinium (UMEC) is', 'indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients', 'with COPD. Salmeterol has long been used for symptoms management of COPD.', 'However, a direct comparison of these maintenance therapies has not been conducted', 'with respect to HRQoL.', 'The primary purpose of this study is to demonstrate improvements in lung function for', 'subjects treated with UMEC/VI compared with UMEC for 24 weeks. The effect of', 'UMC/VI, UMEC, and salmeterol with respect to patient HRQoL measured through', 'patient reported outcomes (PROs) questionnaires, symptoms and lung function will also', 'be evaluated.', '2.2.', 'Brief Background', 'COPD is characterized by an airflow limitation which is not fully reversible, usually', 'progressive and accompanied by a chronic cough, sputum production and dyspnea which', 'can be a major cause of disability and anxiety associated with the disease [Maleki-Yazdi,', '2014]', 'Furthermore, acute exacerbations contribute to the overall severity of disease as these', 'episodes are accompanied by worsened symptoms and are associated with increased', 'decline in lung function and mortality [Wedzicha, 2013; Schmidt, 2014].', 'Pharmacologic therapy is used to improve lung function, reduce symptoms, reduce the', 'frequency and severity of exacerbations, and also to improve health status and exercise', 'tolerance. Maintenance treatment is recommended primarily through the use of LABAs', 'or LAMAs. COPD treatment guidelines recommend an incremental approach to', 'pharmacological treatment as the disease state worsens, involving the use of', 'combinations of drug classes with different or complementary mechanisms [GOLD,', '2015].', 'UMEC/VI inhalation powder is a combination of UMEC (umeclidinium bromide), a', 'LAMA, and VI (Vilanterol), a LABA, delivered via the ELLIPTAR dry powder inhaler', '(DPI). UMEC/VI at a dose of 62.5/25mcg once-daily is marketed in the United States', '(US) and Europe under the trade name ANORO R ELLIPTAR', 'UMEC (62.5 mcg) inhalation powder is marketed in the United States (US) and Europe', 'under', 'the trade name INCRUSE\u00ae ELLIPTAR UMEC (62.5mcg) is indicated as a', 'maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.', 'UMEC (62.5 mcg) improves forced expiratory volume in one second (FEV1), dyspnea', '15']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', 'and HRQoL whether used as monotherapy [Trivedi, 2014; Feldman, 2016] or as an add', 'on to fluticasone propionate and vilanterol (FF/VI) [Siler, 2015]. Salmetrol (50 mcg)', 'DISKUSR is a long-acting broncholdilator that has long been used for the maintenance', 'treatment of COPD [Tashkin, 2010].', 'Clinically important deterioration (CID) is a novel, exploratory composite endpoint', 'which assesses individual deteriorations in lung function and in patient PROs defined by', 'the accepted minimal clinically important difference (MCID), as well as the incidence of', 'moderate to severe exacerbations [Singh, 2016], (Section 7.3.5). CID will be analysed to', 'determine whether UMEC/VI (62.5/25mcg) therapy provides greater clinical stability as', 'compared with UMEC and salmeterol monotherapies.', '3.', 'OBJECTIVE(S) AND ENDPOINT(S)', 'Objectives', 'Enpoints', 'Primary', 'To compare the effect of UMEC/VI', 'Change from baseline in trough Forced', '(62.5/25 mcg once daily) with UMEC', 'Expiratory Volume in One Second', '(62.5 mcg once daily) on lung function', '(FEV1) at week 24', 'Secondary', 'To compare UMEC/VI (62.5/25 mcg', 'Change from baseline in self', 'once daily), UMEC (62.5 mcg once', 'administered computerised (SAC)', 'daily) with salmeterol (50 mcg twice', 'transient dyspnea index (TDI)', 'daily) on patient reported outcomes', '(PROs)', 'Percentage of TDI responders', 'according to SAC TDI score. A', 'responder is defined as a >1 unit', 'improvement in SAC TDI score', 'Assessment of respiratory daily', 'symptoms over 24 weeks using', 'Evaluating Respiratory Symptoms-', 'COPD (E-RS) and its subscales', '(breathlessness, cough and sputum and', 'chest symptoms)', 'Percentage of E-RS responders', 'according to E-RS score (defined as', 'reduction in E-RS score of >2 or >3.35', 'units) from baseline', \"Change from baseline in St George's\", 'Respiratory Questionnaire (SGRQ-C)', 'Percentage of responders according to', 'SGRQ-C total score (defined as a 4', 'point or greater reduction from', '16']\n\n###\n\n", "completion": "END"}